| DIRECT COMPETITOR COMPARISON | |
| EVTC | AMRI | Pvt1 | NRGN | Industry | | Market Cap: | N/A | 279.09M | N/A | 12.43M | N/A | | Employees: | N/A | 1,357 | 1721 | 6 | N/A | | Qtrly Rev Growth (yoy): | N/A | -22.30% | N/A | N/A | N/A | | Revenue (ttm): | N/A | 209.39M | 15.40M1 | 2.65M | N/A | | Gross Margin (ttm): | N/A | 27.94% | N/A | 100.00% | N/A | | EBITDA (ttm): | N/A | 23.73M | N/A | -19.80M | N/A | | Oper Margins (ttm): | N/A | 3.22% | N/A | -757.36% | N/A | | Net Income (ttm): | N/A | 5.63M | N/A | -25.09M | N/A | | EPS (ttm): | N/A | 0.181 | N/A | -0.366 | N/A | | P/E (ttm): | N/A | 48.73 | N/A | N/A | N/A | | PEG (5 yr expected): | N/A | 28.27 | N/A | N/A | N/A | | P/S (ttm): | N/A | 1.32 | N/A | 4.82 | N/A |
|
| NEWS ON DIRECT COMPETITORS | |
| • | NRGN | | Ligand adds cash to Neurogen buyout
Thu 4:16pm -
AP | | • | NRGN | | Neurogen Corporation Receives Notice from NASDAQ Regarding Listing of Securities
Thu 4:12pm -
Business Wire | | • | NRGN | | NEUROGEN CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Thu 1:14pm -
EDGAR Online | | • | NRGN | | InPlay: Neurogen: Ligand will now also pay $600,000 cash to Neurogen stockholders upon closing of the transaction.
Thu 12:35pm -
Briefing.com | | • | NRGN | | Ligand and Neurogen Amend Merger Agreement
Thu 12:32pm -
Business Wire | | • | AMRI | | Bruno name stays put in Capital Region
Wed, Dec 9 -
at bizjournals.com | | • | AMRI | | ALBANY MOLECULAR RESEARCH INC Financials
Fri, Nov 13 -
EDGAR Online Financials | | • | AMRI | | AMRI’s quarterly earnings, revenue down
Mon, Nov 9 -
at bizjournals.com | | • | AMRI | | ALBANY MOLECULAR RESEARCH INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements
Mon, Nov 9 -
EDGAR Online | | • | AMRI | | Q3 2009 Albany Molecular Research Earnings Release - Before Market Open
Mon, Nov 9 -
CCBN | | | All Headlines for these symbols... |
|
|
|
1.27% Nasdaq 
Competitors
